CASI Pharmaceuticals (CASI) News Today $5.46 -0.07 (-1.27%) (As of 10/3/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period CASI Pharmaceuticals (NASDAQ:CASI) Stock, Short Interest ReportOctober 2 at 5:23 AM | benzinga.comCASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200-Day Moving Average of $4.67CASI Pharmaceuticals (NASDAQ:CASI) Shares Cross Above Two Hundred Day Moving Average of $4.67October 2 at 2:22 AM | marketbeat.comCASI Pharmaceuticals (NASDAQ:CASI) shareholders are still up 129% over 1 year despite pulling back 22% in the past weekSeptember 28, 2024 | finance.yahoo.comCASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200 Day Moving Average of $4.60September 25, 2024 | americanbankingnews.comBioInvent International AB (BIX0.DU)September 24, 2024 | sg.finance.yahoo.comCASI Pharmaceuticals (NASDAQ:CASI) Shares Pass Above Two Hundred Day Moving Average of $4.60CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Passes Above 200 Day Moving Average of $4.60September 24, 2024 | marketbeat.comCASI Pharmaceuticals (NASDAQ:CASI) Shares Pass Above 200 Day Moving Average of $4.57CASI Pharmaceuticals (NASDAQ:CASI) Stock Passes Above 200 Day Moving Average of $4.57September 14, 2024 | marketbeat.comCASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCESeptember 4, 2024 | prnewswire.comCASI Pharmaceuticals, Inc. (NASDAQ:CASI) Short Interest UpdateCASI Pharmaceuticals, Inc. (NASDAQ:CASI - Get Free Report) was the target of a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 172,000 shares, a drop of 15.1% from the July 31st total of 202,600 shares. Based on an average trading volume of 240,300 shares, the days-to-cover ratio is presently 0.7 days. Approximately 4.0% of the company's shares are sold short.August 31, 2024 | marketbeat.comCASI Pharmaceuticals (NASDAQ:CASI) Stock Passes Above 200-Day Moving Average of $4.46CASI Pharmaceuticals (NASDAQ:CASI) Shares Cross Above 200 Day Moving Average of $4.46August 27, 2024 | marketbeat.comShort Interest in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Declines By 6.9%CASI Pharmaceuticals, Inc. (NASDAQ:CASI - Get Free Report) was the target of a large decrease in short interest in July. As of July 31st, there was short interest totalling 202,600 shares, a decrease of 6.9% from the July 15th total of 217,600 shares. Currently, 3.2% of the company's stock are short sold. Based on an average daily volume of 240,500 shares, the days-to-cover ratio is presently 0.8 days.August 19, 2024 | marketbeat.comCASI Pharmaceuticals, Inc. Q2 Loss DeclinesAugust 17, 2024 | markets.businessinsider.comCASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTSAugust 16, 2024 | prnewswire.comCASI Pharmaceuticals (NASDAQ:CASI) Share Price Crosses Above Two Hundred Day Moving Average of $4.47CASI Pharmaceuticals (NASDAQ:CASI) Share Price Crosses Above 200 Day Moving Average of $4.47August 13, 2024 | marketbeat.comLigand Reports Second Quarter 2024 Financial ResultsAugust 6, 2024 | finance.yahoo.comCASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above Two Hundred Day Moving Average of $4.44CASI Pharmaceuticals (NASDAQ:CASI) Share Price Passes Above Two Hundred Day Moving Average of $4.44August 3, 2024 | marketbeat.comCASI Pharmaceuticals (NASDAQ:CASI) Earns Hold Rating from Analysts at StockNews.comStockNews.com started coverage on shares of CASI Pharmaceuticals in a report on Saturday. They set a "hold" rating for the company.August 3, 2024 | marketbeat.com3 Promising Biotech Stocks You Can Pick Up for Less Than $10July 29, 2024 | investorplace.comCASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200 Day Moving Average of $4.41CASI Pharmaceuticals (NASDAQ:CASI) Share Price Crosses Above 200-Day Moving Average of $4.41July 26, 2024 | marketbeat.comCASI Pharmaceuticals (NASDAQ:CASI) Now Covered by Analysts at StockNews.comStockNews.com started coverage on shares of CASI Pharmaceuticals in a research report on Friday. They set a "hold" rating on the stock.July 26, 2024 | marketbeat.comCASI Pharmaceuticals, Inc.: CASI Pharmaceuticals Reports Development Relating To Its Disputes With JuventasJuly 20, 2024 | finanznachrichten.deCASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTASJuly 19, 2024 | prnewswire.comCASI Pharmaceuticals, Inc. (NASDAQ:CASI) Short Interest Up 771.1% in JuneCASI Pharmaceuticals, Inc. (NASDAQ:CASI - Get Free Report) was the recipient of a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 529,600 shares, an increase of 771.1% from the June 15th total of 60,800 shares. Currently, 8.2% of the company's stock are short sold. Based on an average daily trading volume, of 231,700 shares, the short-interest ratio is currently 2.3 days.July 11, 2024 | marketbeat.comCASI Pharmaceuticals (NASDAQ:CASI) Shares Pass Above Two Hundred Day Moving Average of $4.42CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Passes Above 200 Day Moving Average of $4.42July 10, 2024 | marketbeat.comCASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVPJuly 8, 2024 | prnewswire.comCASI Pharmaceuticals, Inc. (NASDAQ:CASI) Short Interest Down 23.7% in JuneCASI Pharmaceuticals, Inc. (NASDAQ:CASI - Get Free Report) was the target of a significant drop in short interest during the month of June. As of June 15th, there was short interest totalling 60,800 shares, a drop of 23.7% from the May 31st total of 79,700 shares. Approximately 0.9% of the shares of the company are sold short. Based on an average daily volume of 53,800 shares, the short-interest ratio is currently 1.1 days.July 1, 2024 | marketbeat.comCASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the CompanyJune 26, 2024 | prnewswire.comCASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu HeJune 26, 2024 | prnewswire.comCASI Pharmaceuticals, Inc. (NASDAQ:CASI) Sees Significant Increase in Short InterestCASI Pharmaceuticals, Inc. (NASDAQ:CASI - Get Free Report) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 53,100 shares, a growth of 14.7% from the April 30th total of 46,300 shares. Based on an average trading volume of 193,200 shares, the short-interest ratio is currently 0.3 days. Currently, 0.8% of the company's shares are short sold.June 1, 2024 | marketbeat.comCASI Pharmaceuticals, Inc. (CASI)May 26, 2024 | finance.yahoo.comCASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)May 15, 2024 | prnewswire.comCASI Pharmaceuticals, Inc.: Casi Pharmaceuticals Announces First Quarter 2024 Business And Financial ResultsMay 14, 2024 | finanznachrichten.deCASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | investorplace.comCASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTSMay 14, 2024 | prnewswire.comAnalysts Are Optimistic We'll See A Profit From CASI Pharmaceuticals, Inc. (NASDAQ:CASI)April 24, 2024 | finance.yahoo.comBioInvent International AB: Interim Report January-March 2024April 24, 2024 | finance.yahoo.comCASI Pharmaceuticals updates on Juventas disputeApril 10, 2024 | investing.comCASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTASApril 8, 2024 | finance.yahoo.comRecap: CASI Pharmaceuticals Q4 EarningsMarch 28, 2024 | benzinga.comCASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023March 28, 2024 | markets.businessinsider.comCASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTSMarch 28, 2024 | finance.yahoo.comAptevo Therapeutics: Aptevo Participating in The Springtime Partnering Event, a Bio-Europe ConferenceMarch 18, 2024 | finanznachrichten.deCASI Apr 2024 2.500 callMarch 16, 2024 | finance.yahoo.comPsyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic DivisionMarch 11, 2024 | markets.businessinsider.comAptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare moversMarch 8, 2024 | msn.comCASI Mar 2024 10.000 callMarch 7, 2024 | finance.yahoo.comCASI Mar 2024 7.500 putMarch 7, 2024 | finance.yahoo.comTrading was temporarily halted for "CASI" at 03:03 PM with a stated reason of "LULD pause."March 5, 2024 | marketbeat.comCASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese PatientsMarch 5, 2024 | msn.comTrading was temporarily halted for "CASI" at 09:03 AM with a stated reason of "LULD pause."March 5, 2024 | marketbeat.com Get CASI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter. Email Address 44-year Wall Street Vet: “Permanent devastation is coming to America” (Ad)After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before. The information in this video is crucially valuable. CASI Media Mentions By Week CASI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CASI News Sentiment▼0.380.58▲Average Medical News Sentiment CASI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CASI Articles This Week▼31▲CASI Articles Average Week Get CASI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Genfit News Today Lexeo Therapeutics News Today Aurora Cannabis News Today UroGen Pharma News Today Design Therapeutics News Today Alimera Sciences News Today Zevra Therapeutics News Today Sutro Biopharma News Today Atea Pharmaceuticals News Today Poseida Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CASI) was last updated on 10/3/2024 by MarketBeat.com Staff From Our PartnersWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredMassive NVIDIA Sell-Off: Are We Headed for a Market Collapse?You may have heard about NVIDIA's CEO dumping shares of his own company. He sold 4.4 million shares this ye...Behind the Markets | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CASI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.